Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/12/2025

Steroid Management in ILD Exacerbation

Guideline-Based Recommendations

  • The American Thoracic Society recommends high-dose corticosteroids for acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) despite the absence of controlled trial data, with the majority of patients benefiting from treatment according to international consensus 1.
  • The ATS/ERS/JRS/ALAT guidelines support corticosteroid use in acute IPF exacerbations (weak recommendation, very low-quality evidence), with intravenous doses up to 1 gram per day reported in case series 1.
  • The French guidelines recommend high-dose corticosteroid therapy specifically for acute exacerbation of IPF, though they advise against routine corticosteroid use in stable IPF 2, 3.
  • The recommendation places high value on the extremely high mortality of acute exacerbation (often >50%) and anecdotal reports of benefit, despite lack of randomized controlled trial evidence 1.

Non-IPF Interstitial Lung Diseases

  • For symptomatic ILD with moderate-to-severe impairment, systemic corticosteroids at 0.5-1.0 mg/kg should be initiated, especially for organizing pneumonia patterns 4.
  • Following initial high-dose corticosteroid treatment, transition to steroid-sparing immunosuppression with mycophenolate mofetil or azathioprine as first-line maintenance therapy 4.

Practical Dosing Algorithm

  • For acute exacerbation with respiratory failure or rapidly progressive disease: IV methylprednisolone 500-1000 mg daily for 3 days 1, 4.
  • After initial pulse therapy, transition to oral prednisone 0.5-1.0 mg/kg/day, and taper gradually over weeks to months, aiming for <7.5 mg/day prednisone equivalent for chronic maintenance 4.

Essential Monitoring and Risk Mitigation

  • Pneumocystis jirovecii prophylaxis is mandatory when using high-dose corticosteroids or adding cyclophosphamide 4.
  • Avoid prolonged high-dose monotherapy without adding steroid-sparing agents, as this increases infection risk and long-term morbidity without proven survival benefit 2, 3.
  • Supportive care remains the mainstay of therapy—corticosteroids are adjunctive treatment, not a substitute for appropriate respiratory support and management of precipitating factors 1.